COVID-19 Vaccine and Cancer Treatment
A recent study has found that administering a COVID-19 vaccine to cancer patients within 100 days of starting immune checkpoint inhibitors (ICIs) is associated with increased overall survival.
Researchers from the University of Texas MD Anderson Cancer Center extracted data from patients with non-small cell lung cancer (NSCLC) and melanoma who were treated with ICIs.
- Patients with advanced lung or skin cancer were included in the study.
- The study examined the effect of mRNA vaccines on tumor sensitivity to ICIs.
Administration of a COVID-19 vaccine within 100 days of ICI initiation was associated with increased overall survival.
The study was presented at the annual meeting of the European Society for Medical Oncology.
Author's summary: COVID-19 vaccine increases survival in cancer patients.
More News
- Healthcare Providers Describe Exclusive Human Milk Diet as 'Critical' Need for Premature Infants
- Invisible Assaults: How India’s crime data erases violence against women and children | SabrangIndia
- The Middle East’s Axis of Rape and Pillage
- School of Law Dean Candidates to Present to Campus
- Align Your Day With Nature's Clock for a Stronger, Healthier Heart